Literature DB >> 34248171

Marika Lepage-Légaré1, Sandrine Léger2, Hugo Ricignuolo3, Gabrielle St-Louis2, Thomas Joly-Mischlich4.   

Abstract

Year:  2021        PMID： 34248171      PMCID： PMC8237963          DOI： 10.4212/cjhp.v74i3.3158

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  8 in total

Review 1.  Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Authors:  Jessica C Hassel; Lucie Heinzerling; Jens Aberle; Oliver Bähr; Thomas K Eigentler; Marc-Oliver Grimm; Victor Grünwald; Jan Leipe; Niels Reinmuth; Julia K Tietze; Jörg Trojan; Lisa Zimmer; Ralf Gutzmer
Journal:  Cancer Treat Rev       Date:  2017-05-18       Impact factor: 12.111

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

3.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

4.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

5.  Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.

Authors:  Namrata Nayar; Karen Briscoe; Pablo Fernandez Penas
Journal:  J Immunother       Date:  2016-04       Impact factor: 4.456

Review 6.  Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.

Authors:  Ian T Logan; Saman Zaman; Lama Hussein; Conal M Perrett
Journal:  J Immunother       Date:  2020-04       Impact factor: 4.456

7.  Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.

Authors:  Liezel L Griffin; Laura Cove-Smith; Hana Alachkar; John A Radford; Rebecca Brooke; Kim M Linton
Journal:  JAAD Case Rep       Date:  2018-02-23

Review 8.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.